Christopher G. Hayes - Mar 15, 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
CHIEF LEGAL OFFICER
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
4
Date filed
3/19/2024, 04:31 PM
Previous filing
Nov 16, 2023
Next filing
Jul 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Award $0 +40K +32.46% $0.00 163K Mar 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +80K $0.00 80K Mar 15, 2024 Common Stock 80K $4.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date.
F2 25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.